The 2022 Tandem Meetings | Feasibility of outpatient CAR-T therapy for LBCL
Craig W. Freyer, PharmD, BCOP, Hospital of the University of Pennsylvania, Philadelphia, PA, discusses the considerations for moving CAR-T therapy to the outpatient setting, highlighting data from studies evaluating the safety of outpatient administration of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel) in patients with large B-cell lymphoma (LBCL). In order to deliver outpatient CAR-T therapy safely, it is important to consider both patient and product characteristics, and ensure that patients can transition from inpatient to outpatient care and vice-versa seamlessly. Dr Freyer explains that while small study cohorts support the outpatient use of liso-cel and tisa-cel, the data for axi-cel is limited and indicates that more patients require hospital administration. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
